CSL announces expansion of Illinois plasma therapy manufacturing facility

Core Viewpoint - CSL is expanding its plasma therapy manufacturing facility in Kankakee, Illinois, with a new investment of $1.5 billion, building on over $3 billion already invested in U.S. operations since 2018, which will create at least 300 new jobs and enhance production capabilities for plasma-derived therapies and albumin [1][2]. Group 1: Investment and Job Creation - The new $1.5 billion investment will create at least 300 new pharmaceutical roles and approximately 800 construction and related jobs in the local community [2]. - Since 2018, CSL has invested more than $3 billion in its U.S. operations, creating over 6,500 new American jobs and bringing its total U.S. headcount to nearly 19,000, representing about 60% of CSL's global workforce [2]. Group 2: Manufacturing Expansion and Technology - The Kankakee expansion is expected to be operational by 2031 and will incorporate CSL's Horizon 2 manufacturing process, a patented technology that enhances production yield of immunoglobulin from the same amount of plasma [1][2]. - The expansion aims to improve plasma efficiency and strengthen CSL's U.S. network to support the sustained growth of lifesaving therapies [1]. Group 3: Community and Economic Impact - Local officials, including Illinois Governor JB Pritzker, emphasized the expansion's role in supporting patients and strengthening the regional economy [1]. - The investment is seen as a significant boost to Illinois' life sciences manufacturing sector, reinforcing the state's position as a hub for advanced biologics manufacturing [2]. Group 4: Importance of Plasma-derived Therapies - Plasma-derived therapies treat serious and rare diseases, including hemophilia and primary immunodeficiency, and are essential for many emergency and life-threatening conditions [2]. - The production of plasma-derived medicines is complex and costly, requiring long-term investment and specialized expertise [2].